FIG. 4.
Malignant ascitic cells positive for LRP by IHC (+) showed greater resistance/cell viability to treatment with 50 μM carboplatin than malignant ascitic cells negative for LRP by IHC (−) (p = 0.0043). LRP stratification did not identify sensitivity to paclitaxel using cell viability assay (p > 0.05). Cells were more viable in LRP+ patients after combination (50/1,000) treatment than LRP–patient samples (p = 0.045)